Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC)

Dirk Rades, Roger Nadrowitz, Inga Buchmann, Peter Hunold, Frank Noack, Steven E. Schild, Birgit Meller

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Purpose: The addition of systemic drugs to whole-brain irradiation has not improved the survival of patients with multiple brain metastases, most likely because the agents did not readily cross the blood-brain barrier (BBB). Radiolabeling of cetuximab was performed to investigate whether this antibody crosses the BBB. Case Report: A patient with multiple brain lesions from non-small cell lung cancer was investigated. The largest metastasis (40 × 33 × 27 mm) was selected the reference lesion. On day 1, 200 mg/m2 cetuximab (0.25% hot and 99.75% cold antibody) were given. On day 3, 200 mg/m2 cetuximab (cold antibody) were given. Weekly doses of 250 mg/m2 cetuximab were administered for 3 months. Results: The reference lesion showed enhancement of radiolabeled cetuximab ( 123I-Erbi) on scintigraphy; 123I-Erbi crossed the BBB and accumulated in the lesion. The reference lesion measured 31 × 22 × 21 mm at 4 months. Enhancement of contrast medium was less pronounced. Conclusion: This is the first demonstration of cetuximab crossing the BBB and accumulating in brain metastasis.

Original languageEnglish (US)
Pages (from-to)458-462
Number of pages5
JournalStrahlentherapie und Onkologie
Volume186
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Blood-Brain Barrier
Brain
Antibodies
Therapeutics
Radionuclide Imaging
Contrast Media
Cetuximab
Survival
Pharmaceutical Preparations

Keywords

  • Blood-brain barrier
  • Brain metastases
  • Non-small cell lung cancer
  • Radiolabeled cetuximab

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Medicine(all)

Cite this

Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). / Rades, Dirk; Nadrowitz, Roger; Buchmann, Inga; Hunold, Peter; Noack, Frank; Schild, Steven E.; Meller, Birgit.

In: Strahlentherapie und Onkologie, Vol. 186, No. 8, 08.2010, p. 458-462.

Research output: Contribution to journalArticle

Rades, Dirk ; Nadrowitz, Roger ; Buchmann, Inga ; Hunold, Peter ; Noack, Frank ; Schild, Steven E. ; Meller, Birgit. / Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). In: Strahlentherapie und Onkologie. 2010 ; Vol. 186, No. 8. pp. 458-462.
@article{bdf9b2dbe6a847f1b202ddeab061b5c5,
title = "Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC)",
abstract = "Background and Purpose: The addition of systemic drugs to whole-brain irradiation has not improved the survival of patients with multiple brain metastases, most likely because the agents did not readily cross the blood-brain barrier (BBB). Radiolabeling of cetuximab was performed to investigate whether this antibody crosses the BBB. Case Report: A patient with multiple brain lesions from non-small cell lung cancer was investigated. The largest metastasis (40 × 33 × 27 mm) was selected the reference lesion. On day 1, 200 mg/m2 cetuximab (0.25{\%} hot and 99.75{\%} cold antibody) were given. On day 3, 200 mg/m2 cetuximab (cold antibody) were given. Weekly doses of 250 mg/m2 cetuximab were administered for 3 months. Results: The reference lesion showed enhancement of radiolabeled cetuximab ( 123I-Erbi) on scintigraphy; 123I-Erbi crossed the BBB and accumulated in the lesion. The reference lesion measured 31 × 22 × 21 mm at 4 months. Enhancement of contrast medium was less pronounced. Conclusion: This is the first demonstration of cetuximab crossing the BBB and accumulating in brain metastasis.",
keywords = "Blood-brain barrier, Brain metastases, Non-small cell lung cancer, Radiolabeled cetuximab",
author = "Dirk Rades and Roger Nadrowitz and Inga Buchmann and Peter Hunold and Frank Noack and Schild, {Steven E.} and Birgit Meller",
year = "2010",
month = "8",
doi = "10.1007/s00066-010-2153-y",
language = "English (US)",
volume = "186",
pages = "458--462",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "8",

}

TY - JOUR

T1 - Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC)

AU - Rades, Dirk

AU - Nadrowitz, Roger

AU - Buchmann, Inga

AU - Hunold, Peter

AU - Noack, Frank

AU - Schild, Steven E.

AU - Meller, Birgit

PY - 2010/8

Y1 - 2010/8

N2 - Background and Purpose: The addition of systemic drugs to whole-brain irradiation has not improved the survival of patients with multiple brain metastases, most likely because the agents did not readily cross the blood-brain barrier (BBB). Radiolabeling of cetuximab was performed to investigate whether this antibody crosses the BBB. Case Report: A patient with multiple brain lesions from non-small cell lung cancer was investigated. The largest metastasis (40 × 33 × 27 mm) was selected the reference lesion. On day 1, 200 mg/m2 cetuximab (0.25% hot and 99.75% cold antibody) were given. On day 3, 200 mg/m2 cetuximab (cold antibody) were given. Weekly doses of 250 mg/m2 cetuximab were administered for 3 months. Results: The reference lesion showed enhancement of radiolabeled cetuximab ( 123I-Erbi) on scintigraphy; 123I-Erbi crossed the BBB and accumulated in the lesion. The reference lesion measured 31 × 22 × 21 mm at 4 months. Enhancement of contrast medium was less pronounced. Conclusion: This is the first demonstration of cetuximab crossing the BBB and accumulating in brain metastasis.

AB - Background and Purpose: The addition of systemic drugs to whole-brain irradiation has not improved the survival of patients with multiple brain metastases, most likely because the agents did not readily cross the blood-brain barrier (BBB). Radiolabeling of cetuximab was performed to investigate whether this antibody crosses the BBB. Case Report: A patient with multiple brain lesions from non-small cell lung cancer was investigated. The largest metastasis (40 × 33 × 27 mm) was selected the reference lesion. On day 1, 200 mg/m2 cetuximab (0.25% hot and 99.75% cold antibody) were given. On day 3, 200 mg/m2 cetuximab (cold antibody) were given. Weekly doses of 250 mg/m2 cetuximab were administered for 3 months. Results: The reference lesion showed enhancement of radiolabeled cetuximab ( 123I-Erbi) on scintigraphy; 123I-Erbi crossed the BBB and accumulated in the lesion. The reference lesion measured 31 × 22 × 21 mm at 4 months. Enhancement of contrast medium was less pronounced. Conclusion: This is the first demonstration of cetuximab crossing the BBB and accumulating in brain metastasis.

KW - Blood-brain barrier

KW - Brain metastases

KW - Non-small cell lung cancer

KW - Radiolabeled cetuximab

UR - http://www.scopus.com/inward/record.url?scp=77956628148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956628148&partnerID=8YFLogxK

U2 - 10.1007/s00066-010-2153-y

DO - 10.1007/s00066-010-2153-y

M3 - Article

C2 - 20803287

AN - SCOPUS:77956628148

VL - 186

SP - 458

EP - 462

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 8

ER -